BioVex announced at the annual meeting of the American Association for Cancer Research that the combination of BioVex's proprietary oncolytic agent OncoVEX with first line chemotherapeutic agents resulted in significant lowering of the dose of drug needed to achieve tumour cell killing in pre-clinical models.